ABSTRACT. Objective. To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders (PDD).Methods. In this 8-week, randomized, double-blind, placebo-controlled trial, risperidone/placebo solution (0.01-0.06 mg/kg/day) was administered to 79 children who were aged 5 to 12 years and had PDD. Behavioral symptoms were assessed using the Aberrant Behavior Checklist (ABC), Nisonger Child Behavior Rating Form, and Clinical Global Impression-Change. Safety assessments included vital signs, electrocardiogram, extrapyramidal symptoms, adverse events, and laboratory tests.Results. Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the ABC (primary endpoint) compared with those who were taking placebo. By study endpoint, risperidone-treated subjects exhibited a 64% improvement over baseline in the irritability score almost double that of placebo-treated subjects (31%). Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the ABC; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom. More risperidone-treated subjects (87%) showed global improvement in their condition compared with the placebo group (40%). Somnolence, the most frequently reported adverse event, was noted in 72.5% versus 7.7% of subjects (risperidone vs placebo) and seemed manageable with dose/dose-schedule modification. Risperidone-treated subjects experienced statistically significantly greater increases in weight (2.7 vs 1.0 kg), pulse rate, and systolic blood pressure. Extrapyramidal symptoms scores were comparable between groups.Conclusions. Risperidone was well tolerated and efficacious in treating behavioral symptoms associated with PDD in children. Pediatrics 2004;114:e634-e641. URL: www.pediatrics.org/cgi/doi/10.1542/peds.2003-0264-F; autistic disorder, pervasive developmental disorders, risperidone.ABBREVIATIONS. PDD, pervasive developmental disorders; EPS, extrapyramidal symptom; CARS, Childhood Autism Rating Scale; ESRS, Extrapyramidal Symptom Rating Scale; ABC, Aberrant Behavior Checklist; N-CBRF, Nisonger Child Behavior Rating Form; VAS, Visual Analog Scale; CGI-C, Clinical Global Impression-Change; ITT, intention-to-treat; RUPP, Research Units on Pediatric Psychopharmacology. T he pervasive developmental disorders (PDD) are a group of neuropsychiatric disorders that include autistic disorder, Asperger's disorder, childhood disintegrative disorder, Rett's disorder, and PDD not otherwise specified. 1 These disorders are characterized by atypical development in social, communicative, and behavior areas. Onset typically occurs within the first years of life. Prevalence rates as high as 63 per 10 000 children have recently been ...

This publication is intended to provide accurate and authoritative information regarding the subject matter covered. It is sold with the understanding that the publisher is not engaged in rendering medical, psychological, financial, legal, or other professional services. The recommended doses of medications cited in this newsletter are not meant to serve as a guide for prescribing of medications. Physicians, please check the manufacturer's product information sheet or the PHYSICIAN'S DESK REFERENCE for further information and contraindications. 1 • CAPN 21(3) Educational Objectives Upon completion of this activity, participants should be able to: • Review the indications for the use of anti-psychotic medications in children and adolescents with Autism Spectrum Disorders • Develop an understanding of metabolic side effects of anti-psychotic medications in this age group and explore management options for these side effects. Target Audience This CME activity is intended for child and adult psychiatrists, pediatricians and other healthcare professionals with an interest in the psychopharmacology and treatment practices for child and adolescent psychiatric disorders.

No abstract

No abstract